Europe: Orphan Drug Products Account for Annual Sales of Over $6 billion Says New Report

Piribo, the online destination for Pharma intelligence, has added a new report.

According to the report “Orphan Drug Markets in Europe” the first marketing authorisations for orphan drugs in Europe occurred over 10 years ago. Since then there have been over 60 designated orphan products. These products now account for annual sales of more than $6 billion.

According to the report the development and marketing of orphan drugs has not traditionally been an area of interest for major pharmaceutical companies, reflecting the view that orphan drugs were specialty products with limited market potential thus offering a poor fit for companies based upon the blockbuster model. However, a number of major companies have reassessed their strategy with respect to orphan drugs and five of the top ten have made explicit commitments to the development of such drugs. This has seen a number of changes in the orphan drug landscape and further developments are likely, especially from some of those not yet active in the field.

View the report “Orphan Drug Markets in Europe”

press@reportbuyer.com

t. 44 (0) 20 7060 7474

Pharmaceutical-market-research.com is the source for information products concerning the global biotechnology, healthcare, medical device and pharmaceutical industries. With over 26,000 market reports available, executives can find a current and comprehensive range of specialised intelligence. www.pharmaceutical-market-research.com is a service from Piribo Ltd, which was founded in 2004.

Tags: